查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083374

2026 年至 2035 年藥物發現服務的市場機會、成長促進因素、產業趨勢分析與預測。

Drug Discovery Services Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球藥物研發服務市場預計到 2025 年將價值 192 億美元，並將以 13.5% 的複合年成長率成長，到 2035 年達到 673 億美元。

藥物發現服務市場-IMG1

隨著製藥和生技公司越來越依賴外部研究合作夥伴來提高藥物發現效率、縮短研發週期並最佳化研發投資，市場持續擴張。現代藥物研發日益複雜、先進計算方法的廣泛應用以及對創新療法的需求不斷成長，都在加速專業藥物發現服務供應商的使用。未來成長的關鍵促進因素之一是向策略外包的轉變。企業正在與合約研究組織 (CRO) 建立長期合作關係，以利用其先進的能力和靈活的研究模式。生物製藥在開發平臺中的比例不斷提高，以及人工智慧 (AI) 在整個藥物發現工作流程中的應用日益廣泛，進一步拓展了市場機會。基於人工智慧的平台正在提高標靶識別、分子篩檢和候選化合物評估等領域的效率，幫助研究人員更快、更準確地做出決策。全球藥物研發投資每年超過 2500 億美元，並且持續成長，這支撐了對藥物發現外包解決方案的需求，因為企業希望在整個創新過程中提高速度、擴充性和成本控制。

市場範圍
開始年份 2025
預測期 2026-2035
起始金額 192億美元
預測金額 673億美元
複合年成長率 13.5%

到2025年，標靶篩選領域將佔據10.3%的市場佔有率，凸顯其作為早期環節的重要性，對整個藥物研發專案的成敗至關重要。該領域專注於識別和評估具有治療特定疾病潛力的生物標靶。計算生物學、數據分析和人工智慧驅動的研究平台的進步，拓展了科學家探索新療法和改進目標檢驗流程的能力。

預計到2025年，製藥和生物技術領域將佔據68.8%的市場。該領域的強勁地位得益於製藥研發公司日益依賴外包研究服務，以增強自身能力、縮短藥物研發週期並控制營運成本。與合約研究組織（CRO）的合作使公司能夠利用專業知識和先進技術，同時在整個研究項目中保持柔軟性。

到2025年，北美將佔據藥物研發服務市場45.56%的佔有率。該地區的主導地位得益於眾多製藥和生物技術公司、先進的研究基礎設施、對生命科學創新的大量投資，以及支持先進藥物研發活動的法律規範。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

  • 產業生態系分析
  • 影響產業的因素
    • 成長促進因素
      • 研發支出增加
      • 慢性病盛行率增加
      • 對新型治療藥物的需求日益成長
      • 精準醫療和標靶治療的發展
    • 產業潛在風險與挑戰
      • 藥物研發方面的嚴格監管
      • 藥物研發失敗率高
    • 市場機遇
      • 將人工智慧和數位技術應用於藥物研發
      • 外包業務向新興市場的擴張
  • 成長潛力分析
  • 技術與創新展望
    • 最新科技趨勢
    • 新興技術
  • 價格趨勢分析
  • 監理情勢
  • 波特的分析
  • PESTLE分析
  • 專利分析
  • 未來市場趨勢
  • 人工智慧和生成式人工智慧對市場的影響
  • 投資與資金籌措分析

第4章 競爭情勢

  • 介紹
  • 企業市佔率分析
    • 北美洲
    • 歐洲
    • 亞太地區
  • 企業矩陣分析
  • 主要市場公司的競爭分析
  • 競爭定位矩陣
  • 主要進展
    • 併購
    • 夥伴關係和聯盟
    • 新產品發布
    • 業務拓展計劃

第5章 市場估價與預測：依製程分類，2022-2035年

  • 目標選擇
  • 目標檢驗
  • 點擊閱讀搜尋
  • 先導藥物最適化
  • 候選化合物的檢驗

第6章 市場估計與預測：依類型分類，2022-2035年

  • 化學服務
  • 生物服務

第7章 市場估計與預測：依藥物類型分類，2022-2035年

  • 小分子藥物
  • 高分子量藥物

第8章 市場估計與預測：依治療領域分類，2022-2035年

  • 糖尿病
  • 神經病學
  • 腫瘤學
  • 感染疾病
  • 其他治療領域

第9章 市場估計與預測：依最終用途分類，2022-2035年

  • 製藥和生物技術公司
  • 受託研究機構
  • 其他最終用戶

第10章 市場估價與預測：依地區分類，2022-2035年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • UAE

第11章：公司簡介

  • Charles River Laboratories International, Inc.
  • WuXi AppTec Co., Ltd.
  • Pharmaron Beijing Co., Ltd.
  • Labcorp Drug Development
  • Evotec SE
  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific SE
  • Syngene International Limited
  • Curia Global, Inc.
  • Sai Life Sciences Limited
  • Aragen Life Sciences Ltd.
  • Sygnature Discovery Ltd.
  • BioDuro-Sundia
  • Aurigene Pharmaceutical Services Ltd.
  • Selvita SA
簡介目錄
Product Code: 6004

The Global Drug Discovery Services Market was valued at USD 19.2 billion in 2025 and is estimated to grow at a CAGR of 13.5% to reach USD 67.3 billion by 2035.

Drug Discovery Services Market - IMG1

The market is experiencing expansion as pharmaceutical and biotechnology companies increasingly rely on external research partners to improve discovery efficiency, reduce development timelines, and optimize research investments. The growing complexity of modern drug development, increasing adoption of advanced computational approaches, and rising demand for innovative therapies are accelerating the use of specialized drug discovery service providers. A major factor shaping future growth is the transition toward strategic outsourcing, where companies are forming long-term collaborations with contract research organizations (CROs) to access advanced capabilities and flexible research models. The rising presence of biologics in development pipelines and the growing application of artificial intelligence across discovery workflows are further enhancing market opportunities. AI-based platforms are improving efficiency in areas such as target identification, molecule screening, and candidate assessment, helping researchers make faster and more informed decisions. Continued pharmaceutical R&D investment, with global spending exceeding USD 250 billion annually, is supporting demand for outsourced discovery solutions as companies seek greater speed, scalability, and cost control throughout the innovation process.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$19.2 Billion
Forecast Value$67.3 Billion
CAGR13.5%

The target selection segment held a 10.3% share in 2025, highlighting its importance as an early-stage activity that influences the overall success of drug development programs. This segment focuses on identifying and evaluating biological targets that can potentially deliver therapeutic benefits for specific medical conditions. Advancements in computational biology, data analytics, and AI-enabled research platforms have expanded the ability of scientists to explore new therapeutic opportunities and improve target validation processes.

The pharmaceutical and biotechnology segment held a 68.8% share in 2025. The strong position of this segment is supported by the increasing dependence of drug developers on outsourced research services to enhance internal capabilities, accelerate discovery timelines, and manage operational costs. CRO partnerships allow companies to access specialized expertise and advanced technologies while maintaining flexibility throughout research programs.

North America Drug Discovery Services Market held a 45.56% share in 2025. The region's leadership is supported by the strong presence of pharmaceutical and biotechnology companies, advanced research infrastructure, significant investment in life sciences innovation, and a regulatory framework that supports advanced drug discovery and development activities.

Major players operating in the global drug discovery services market are WuXi AppTec Co., Ltd.; Charles River Laboratories International, Inc.; Evotec SE; Pharmaron Beijing Co., Ltd.; Thermo Fisher Scientific Inc. (PPD); Eurofins Scientific SE; Labcorp Drug Development; Syngene International Limited; Curia Global, Inc.; BioDuro-Sundia; Sai Life Sciences Limited; Selvita S.A.; Aragen Life Sciences Ltd.; Aurigene Pharmaceutical Services Ltd.; and Sygnature Discovery Ltd. Key strategies adopted by companies in the drug discovery services market include expanding service portfolios, investing in AI-driven research platforms, strengthening technology capabilities, and building strategic partnerships with pharmaceutical and biotechnology firms. Leading providers are focusing on integrated discovery solutions that cover multiple stages of research to improve customer retention and create long-term collaborations. Companies are also increasing investments in automation, advanced analytics, and specialized scientific expertise to enhance efficiency and deliver faster outcomes.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Research approach
  • 1.2 Quality commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research trail & confidence scoring
    • 1.3.1 Research trail components
    • 1.3.2 Scoring components
  • 1.4 Data collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation for any one approach
  • 1.7 Market estimates & forecasts parameters
  • 1.8 Forecast model
    • 1.8.1 Quantified market impact analysis
      • 1.8.1.1 Mathematical impact of growth parameters on forecast
  • 1.9 Research transparency addendum
    • 1.9.1 Source attribution framework
    • 1.9.2 Quality assurance metrics
    • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
    • 2.1.1 Business trends
    • 2.1.2 Process trends
    • 2.1.3 Type trends
    • 2.1.4 Drug type trends
    • 2.1.5 Therapeutic area trends
    • 2.1.6 End use trends
    • 2.1.7 Regional trends
  • 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing R&D expenditure
      • 3.2.1.2 Rising prevalence of chronic diseases
      • 3.2.1.3 Rising demand for novel therapeutic drugs
      • 3.2.1.4 Growth in precision medicine and targeted therapies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulations governing drug discovery
      • 3.2.2.2 High attrition rates in drug development
    • 3.2.3 Market opportunities
      • 3.2.3.1 Integration of AI and digital technologies in drug discovery
      • 3.2.3.2 Expansion of outsourcing to emerging markets
  • 3.3 Growth potential analysis
  • 3.4 Technology and innovation landscape
    • 3.4.1 Current technological trends
    • 3.4.2 Emerging technologies
  • 3.5 Pricing trend analysis (Driven by primary research)
  • 3.6 Regulatory landscape (Driven by primary research)
    • 3.6.1 North America
    • 3.6.2 Europe
    • 3.6.3 Asia Pacific
    • 3.6.4 Latin America
    • 3.6.5 MEA
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Patent analysis
  • 3.10 Future market trends
  • 3.11 Impact of AI and Generative AI on the market (Driven by primary research)
  • 3.12 Investment & funding analysis (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 North America
    • 4.2.2 Europe
    • 4.2.3 Asia Pacific
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Process, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Target selection
  • 5.3 Target validation
  • 5.4 Hit-to-lead identification
  • 5.5 Lead optimization
  • 5.6 Candidate validation

Chapter 6 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Chemistry services
  • 6.3 Biological services

Chapter 7 Market Estimates and Forecast, By Drug Type, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Small-molecule drugs
  • 7.3 Large-molecule drugs

Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 Diabetes
  • 8.3 Neurology
  • 8.4 Oncology
  • 8.5 Infectious diseases
  • 8.6 Other therapeutic areas

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

  • 9.1 Key trends
  • 9.2 Pharmaceutical & biotechnology companies
  • 9.3 Contract Research Organizations
  • 9.4 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 France
    • 10.3.3 UK
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 South Africa
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Charles River Laboratories International, Inc.
  • 11.2 WuXi AppTec Co., Ltd.
  • 11.3 Pharmaron Beijing Co., Ltd.
  • 11.4 Labcorp Drug Development
  • 11.5 Evotec SE
  • 11.6 Thermo Fisher Scientific Inc.
  • 11.7 Eurofins Scientific SE
  • 11.8 Syngene International Limited
  • 11.9 Curia Global, Inc.
  • 11.10 Sai Life Sciences Limited
  • 11.11 Aragen Life Sciences Ltd.
  • 11.12 Sygnature Discovery Ltd.
  • 11.13 BioDuro-Sundia
  • 11.14 Aurigene Pharmaceutical Services Ltd.
  • 11.15 Selvita S.A.